Merck no longer in talks to buy Revolution Medicines, WSJ reports

Merck has stopped discussions to acquire cancer drug maker Revolution Medicines. The companies could not agree on a price for the deal. Talks might restart later. Revolution Medicines has a promising experimental cancer drug. This drug is in late-stage trials and has received a fast-track review from the FDA. The potential deal was valued between $28 billion and $32 billion.